GRAIL, Inc. (GRAL): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$299.01M

Year ended 2025-12-31

-$294.75M

Trailing 12 months to 2026-06-30

2023-01-01 Operating Cash Flow (USD) 2025-12-31

Period ended	Operating Cash Flow	Change YoY	Source filing
2025-12-31	-$299.01M	n/m	2026-03-12, From 2025-01-01
2024-12-31	-$577.16M	n/m	2026-03-12, From 2024-01-01
2023-12-31	-$595.80M	n/a	2026-03-12, From 2023-01-01
2023-01-01, Fiscal 2022	-$561.31M	n/a	2025-03-05, From 2022-01-03

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
GRAIL, Inc. (GRAL)	2025-12-31	-$299.01M	n/m
Biodesix Inc (BDSX)	2025-12-31	-$23.27M	n/m
BillionToOne, Inc. (BLLN)	2025-12-31	$24.59M	n/m
Personalis, Inc. (PSNL)	2025-12-31	-$74.95M	n/m
Fulgent Genetics, Inc. (FLGT)	2025-12-31	-$101.64M	n/m
Exagen Inc. (XGN)	2025-12-31	-$13.62M	n/m
Castle Biosciences Inc (CSTL)	2025-12-31	$64.35M	-0.8%
CareDx, Inc. (CDNA)	2025-12-31	$42.03M	+10.5%
Veracyte, Inc. (VCYT)	2025-12-31	$136.31M	+81.5%

Compare GRAL, BDSX, BLLN, PSNL side by side · Screen every company in Services-Medical Laboratories ↗